Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 10;7(10):339.
doi: 10.3390/jcm7100339.

Use of Psychotropic Drugs among Children and Adolescents with Autism Spectrum Disorders in Denmark: A Nationwide Drug Utilization Study

Lotte Rasmussen  1 , Niels Bilenberg  2 , Martin Thomsen Ernst  3   4 , Sidsel Abitz Boysen  5 , Anton Pottegård  6
Affiliations

Use of Psychotropic Drugs among Children and Adolescents with Autism Spectrum Disorders in Denmark: A Nationwide Drug Utilization Study

Lotte Rasmussen et al. J Clin Med. .

Abstract

Children with autism spectrum disorder (ASD) have a considerable use of psychotropics. Leveraging nationwide registry data, we aimed to describe the use of psychotropics among children and adolescents with ASD in Denmark. Use of melatonin and attention-deficit/hyperactivity disorder (ADHD) medication increased from 2010 to 2017, while there were limited changes in use of antidepressants and antipsychotics. Thirty percent of the identified children used psychotropics in 2017 most commonly ADHD medication (17%) and melatonin (13%). Methylphenidate, sertraline and risperidone were most often prescribed. Most children filled more than one prescription and, across drug classes, at least 38% received treatment two years after treatment initiation. Use of psychotropics followed psychiatric comorbidities. Comorbidities did not affect age at treatment initiation. Use of psychotropics varied according to age and sex with limited use in the youngest children. In summary, psychotropic drug use has increased in children with ASD mainly due to an increase in the use of ADHD medication and melatonin. In accordance with previous studies, use seems to follow comorbidities. The long treatment duration underlines the need to investigate long-term effects of psychotropic drug use in children with ASD.

Keywords: Denmark; adolescent; autism spectrum disorder; central nervous system stimulants; child; drug utilization; prevalence; psychotropic drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript and in the decision to publish the results.

Figures

Figure 1
Figure 1
One-year prevalence proportion for the use (≥2 prescriptions) of attention-deficit/hyperactivity disorder (ADHD) medication, antidepressants, and antipsychotics from 2010 to 2017 and melatonin from 2012 to 2017 in children and adolescents 3–17 years old with autism spectrum disorder (ASD).
Figure 2
Figure 2
Age-stratified prevalence proportion for the use of ADHD medication, antidepressants, antipsychotics, and melatonin in 2017 for children and adolescents 6–17 years old with ASD.
Figure 3
Figure 3
One-year prevalence proportion for the use of ADHD medication, antidepressants, antipsychotics, and melatonin in 2017 in children and adolescents 6–17 years old with ASD by psychiatric comorbidity.
See this image and copyright information in PMC

References

    1. Lai M.-C., Lombardo M.V., Baron-Cohen S. Autism. Lancet. 2014;383:896–910. doi: 10.1016/S0140-6736(13)61539-1. - DOI - PubMed
    1. Lauritsen M.B. Autism spectrum disorders. Eur. Child Adolesc. Psychiatry. 2013;22:37–42. doi: 10.1007/s00787-012-0359-5. - DOI - PubMed
    1. Elsabbagh M., Divan G., Koh Y.-J., Kim Y.S., Kauchali S., Marcín C., Montiel-Nava C., Patel V., Paula C.S., Wang C., et al. Global prevalence of autism and other pervasive developmental disorders: Global epidemiology of autism. Autism Res. 2012;5:160–179. doi: 10.1002/aur.239. - DOI - PMC - PubMed
    1. Lyall K., Croen L., Daniels J., Fallin M.D., Ladd-Acosta C., Lee B.K., Park B.Y., Snyder N.W., Schendel D., Volk H., et al. The changing epidemiology of autism spectrum disorders. Annu. Rev. Public Health. 2017;38:81–102. doi: 10.1146/annurev-publhealth-031816-044318. - DOI - PMC - PubMed
    1. Atladottir H.O., Gyllenberg D., Langridge A., Sandin S., Hansen S.N., Leonard H., Gissler M., Reichenberg A., Schendel D.E., Bourke J., et al. The increasing prevalence of reported diagnoses of childhood psychiatric disorders: A descriptive multinational comparison. Eur. Child Adolesc. Psychiatry. 2014;24:173–183. doi: 10.1007/s00787-014-0553-8. - DOI - PubMed

Grants and funding

LinkOut - more resources